Cite
HARVARD Citation
Lassman, A. et al. (2019). Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro-oncology. 21 (1), pp. 106-114. [Online].